$ABEO
ABEONA THERAPEUTICS INC. Stock $abeo

$abeo Overview Financials Valuation SEC Filings Company Website

2018 Q3 Form 10-Q Financial Statement

#000114420418043278 Filed on August 09, 2018

Income Statement

Concept	2018 Q3	2018 Q2	2017 Q2
Revenue	$1.709M	$819.0K	$217.0K
YoY Change	680.37%	277.42%	1.4%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.970M	$4.630M	$2.640M
YoY Change	129.03%	75.38%	-29.22%
% of Gross Profit
Research & Development	$13.15M	$7.916M	$5.808M
YoY Change	301.28%	36.29%	92.45%
% of Gross Profit
Depreciation & Amortization	$505.0K	$290.0K	$207.0K
YoY Change	265.94%	40.1%	14.36%
% of Gross Profit
Operating Expenses	$13.15M	$7.916M	$5.808M
YoY Change	301.28%	36.29%	92.45%
Operating Profit	-$16.92M	-$12.56M	-$8.440M
YoY Change	215.48%	48.78%	25.69%
Interest Expense	$500.0K	$310.0K	$160.0K
YoY Change	2400.0%	93.75%	1500.0%
% of Operating Profit
Other Income/Expense, Net	$497.0K	$314.0K	$161.0K
YoY Change	2515.79%	95.03%	1241.67%
Pretax Income	-$16.42M	-$12.24M	-$8.280M
YoY Change	207.49%	47.83%	23.58%
Income Tax
% Of Pretax Income
Net Earnings	-$16.42M	-$12.24M	-$8.279M
YoY Change	207.3%	47.88%	23.51%
Net Earnings / Revenue	-960.74%	-1494.87%	-3815.21%
Basic Earnings Per Share
Diluted Earnings Per Share	-$339.8K	-$258.8K	-$205.6K
COMMON SHARES
Basic Shares Outstanding	47.94M shares	47.31M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q3	2018 Q2	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$112.2M	$119.8M	$58.30M
YoY Change	98.58%	105.49%	69.97%
Cash & Equivalents	$33.60M	$49.99M	$58.30M
Short-Term Investments	$78.60M	$69.90M
Other Short-Term Assets	$2.000M	$1.900M	$900.0K
YoY Change	11.11%	111.11%	350.0%
Inventory
Prepaid Expenses
Receivables	$400.0K	$0.00	$100.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$114.6M	$121.8M	$59.30M
YoY Change	96.15%	105.44%	71.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.245M	$8.007M	$700.0K
YoY Change	1220.71%	1043.86%	16.67%
Goodwill	$32.47M	$32.47M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$600.0K	$600.0K	$100.0K
YoY Change	500.0%	500.0%	0.0%
Total Long-Term Assets	$46.03M	$44.87M	$37.36M
YoY Change	23.39%	20.11%	-5.66%
TOTAL ASSETS
Total Short-Term Assets	$114.6M	$121.8M	$59.30M
Total Long-Term Assets	$46.03M	$44.87M	$37.36M
Total Assets	$160.6M	$166.7M	$96.66M
YoY Change	67.79%	72.46%	30.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.33M	$5.783M	$3.617M
YoY Change	416.55%	59.88%	72.24%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$10.33M	$5.783M	$4.219M
YoY Change	297.35%	37.07%	-51.51%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$3.400M
YoY Change	-100.0%	-100.0%	-15.0%
Total Long-Term Liabilities	$0.00	$0.00	$3.400M
YoY Change	-100.0%	-100.0%	-15.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.33M	$5.783M	$4.219M
Total Long-Term Liabilities	$0.00	$0.00	$3.400M
Total Liabilities	$10.33M	$5.783M	$7.581M
YoY Change	75.1%	-23.72%	-40.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$392.7M	-$376.3M	-$346.0M
YoY Change		8.76%
Common Stock	$543.0M	$537.2M	$435.1M
YoY Change		23.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$150.2M	$160.9M	$89.08M
YoY Change
Total Liabilities & Shareholders Equity	$160.6M	$166.7M	$96.66M
YoY Change	67.79%	72.46%	30.27%

Cashflow Statement

Concept	2018 Q3	2018 Q2	2017 Q2
OPERATING ACTIVITIES
Net Income	-$16.42M	-$12.24M	-$8.279M
YoY Change	207.3%	47.88%	23.51%
Depreciation, Depletion And Amortization	$505.0K	$290.0K	$207.0K
YoY Change	265.94%	40.1%	14.36%
Cash From Operating Activities	-$9.040M	-$9.020M	-$4.980M
YoY Change	33.53%	81.12%	60.13%
INVESTING ACTIVITIES
Capital Expenditures	-$1.660M	-$3.420M	-$10.00K
YoY Change	1975.0%	34100.0%	-91.67%
Acquisitions
YoY Change
Other Investing Activities	-$8.780M	-$69.85M
YoY Change
Cash From Investing Activities	-$10.43M	-$73.28M	-$10.00K
YoY Change	12937.5%	732700.0%	-91.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.080M	570.0K	90.00K
YoY Change	-39.13%	533.33%	-40.0%
NET CHANGE
Cash From Operating Activities	-9.040M	-9.020M	-4.980M
Cash From Investing Activities	-10.43M	-73.28M	-10.00K
Cash From Financing Activities	3.080M	570.0K	90.00K
Net Change In Cash	-16.39M	-81.73M	-4.900M
YoY Change	815.64%	1567.96%	59.09%
FREE CASH FLOW
Cash From Operating Activities	-$9.040M	-$9.020M	-$4.980M
Capital Expenditures	-$1.660M	-$3.420M	-$10.00K
Free Cash Flow	-$7.380M	-$5.600M	-$4.970M
YoY Change	10.31%	12.68%	66.22%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1374000	USD
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2612000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	USD
CY2018Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	560000	USD
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7505000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5664000	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4627000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2642000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47327785	shares
CY2018Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	69852000	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	174000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	361000	USD
CY2017Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	158000	USD
CY2018Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	87000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	464000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	457000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4573000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2735000	USD
	dei	Entity Registrant Name EntityRegistrantName	ABEONA THERAPEUTICS INC.
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8007000	USD
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46888108	shares
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49990000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	137750000	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	346000	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
CY2018Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	346000	USD
CY2018Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	47000	USD
CY2017Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	107000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13526000	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	346000	USD
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	2247000	USD
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1937000	USD
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	1
CY2018Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	172000	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	346000	USD
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2018Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	819000	USD
CY2017Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	217000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3417000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	403000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2735000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7916000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5808000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16078000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8006000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	121826000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	140592000	USD
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	170098000	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.09	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.09	pure
CY2018Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	290000	USD
CY2017Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	207000	USD
	abeo	Revenue Revenue	3417000	USD
CY2018Q2	abeo	Revenue Revenue	819000	USD
CY2018Q2	us-gaap	Grants Receivable GrantsReceivable	13850000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2612000	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3803000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3977000	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0000318306
	abeo	Allocated Share Based Compensation Expense Restricted Stock AllocatedShareBasedCompensationExpenseRestrictedStock	344000	USD
	abeo	Allocated Share Based Compensation Expense Restricted Stock AllocatedShareBasedCompensationExpenseRestrictedStock	686000	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	USD
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	127000	USD
CY2018Q2	us-gaap	Goodwill Goodwill	32466000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	32466000	USD
CY2018Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
	us-gaap	Costs And Expenses CostsAndExpenses	24047000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	14127000	USD
CY2018Q2	us-gaap	Costs And Expenses CostsAndExpenses	12833000	USD
CY2017Q2	us-gaap	Costs And Expenses CostsAndExpenses	8657000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0244	pure
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0265	pure
CY2018Q1	us-gaap	Cumulative Effect On Retained Earnings Net Of Tax1 CumulativeEffectOnRetainedEarningsNetOfTax1	3663000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2673000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1900000	USD
CY2018Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-12014000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8440000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20630000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13724000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	5005000	USD
CY2018Q2	us-gaap	Assets Assets	166697000	USD
CY2017Q4	us-gaap	Assets Assets	178766000	USD
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-60000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-27000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-798000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	712000	USD
	dei	Trading Symbol TradingSymbol	ABEO
CY2018Q2	abeo	Proceeds From Grant Received ProceedsFromGrantReceived	3400000	USD
CY2017Q4	abeo	Proceeds From Grant Received ProceedsFromGrantReceived	2600000	USD
CY2018Q1	abeo	Proceeds From Grant Received ProceedsFromGrantReceived	800000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	473000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	203000	USD
CY2018Q2	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	317000	USD
CY2017Q2	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	164000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.36
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.87
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	172000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	172000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	481000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1685000	USD
CY2018Q2	abeo	Sharebased Compensation Arrangement By Sharebased Payment Award Option Grants In Period Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantsInPeriodWeightedAverageGrantDateFairValue	12.87	USD
	abeo	Sharebased Compensation Arrangement By Sharebased Payment Award Option Grants In Period Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantsInPeriodWeightedAverageGrantDateFairValue	11.36	USD
CY2018Q2	abeo	Interest And Other Expense InterestAndOtherExpense	3000	USD
CY2017Q2	abeo	Interest And Other Expense InterestAndOtherExpense	3000	USD
	abeo	Interest And Other Expense InterestAndOtherExpense	6000	USD
	abeo	Interest And Other Expense InterestAndOtherExpense	5000	USD
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-356129000	USD
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	47943285	shares
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-42000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3390000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-77000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	170098000	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	5783000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2393000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	467000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	198000	USD
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	314000	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	161000	USD
CY2018Q1	abeo	Stock Issued During Period Value Warrants Two Exercised StockIssuedDuringPeriodValueWarrantsTwoExercised	144000	USD
CY2018Q2	abeo	Stock Issued During Period Value Warrants Two Exercised StockIssuedDuringPeriodValueWarrantsTwoExercised	89000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20163000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-11700000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-8279000	USD
CY2018Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3214000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13104000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10839000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5783000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5607000	USD
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2018Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	47182691	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40262824	shares
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	47303518	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40270879	shares
CY2018Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3061000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6923000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	84000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	69852000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
CY2018Q2	us-gaap	Liabilities Liabilities	5783000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	8668000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-8463000	USD
CY2018Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	169199000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2166000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	85000	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	473000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	469000	USD
CY2018Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	536733000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	529421000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2399000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	85000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-87480000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10838000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-376292000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-359792000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	160914000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	138030000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69142000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50550000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58304000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	166697000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	178766000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	58304000	USD
	us-gaap	Interest Paid Net InterestPaidNet	6000	USD
	us-gaap	Interest Paid Net InterestPaidNet	5000	USD
CY2018Q2	abeo	Other Assets And Restricted Cash OtherAssetsAndRestrictedCash	595000	USD
CY2017Q4	abeo	Other Assets And Restricted Cash OtherAssetsAndRestrictedCash	357000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2612000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-302000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-76775000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-84000	USD
	abeo	Cash And Cash Equivalents Restricted Cash CashAndCashEquivalentsRestrictedCash	50550000	USD
	abeo	Cash And Cash Equivalents Restricted Cash CashAndCashEquivalentsRestrictedCash	58304000	USD
CY2018Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	69852000	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	4000000	USD
CY2018Q2	abeo	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice	16.27
	abeo	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice	14.38

Files In Submission

Name	View Source	Status
0001144204-18-043278-index-headers.html	Edgar Link	pending
0001144204-18-043278-index.html	Edgar Link	pending
0001144204-18-043278.txt	Edgar Link	pending
0001144204-18-043278-xbrl.zip	Edgar Link	pending
abeo-20180630.xml	Edgar Link	completed
abeo-20180630.xsd	Edgar Link	pending
abeo-20180630_cal.xml	Edgar Link	unprocessable
abeo-20180630_def.xml	Edgar Link	unprocessable
abeo-20180630_lab.xml	Edgar Link	unprocessable
abeo-20180630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv499937_10q.htm	Edgar Link	pending
tv499937_ex31-1.htm	Edgar Link	pending
tv499937_ex31-2.htm	Edgar Link	pending
tv499937_ex32-1.htm	Edgar Link	pending
tv499937_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABEO
ABEONA THERAPEUTICS INC. Stock $abeo

2018 Q3 Form 10-Q Financial Statement

#000114420418043278 Filed on August 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABEO ABEONA THERAPEUTICS INC. Stock $abeo

2018 Q3 Form 10-Q Financial Statement

#000114420418043278 Filed on August 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABEO
ABEONA THERAPEUTICS INC. Stock $abeo